Health Canada has approved Pfizer's new Covid-19 vaccine

Health Canada has recently given its approval for the use of the new COVID-19 vaccine called Comirnaty by Pfizer-BioNTech, which is effective against the Omicron XBB.1.5 subvariant. According to the Ministry of Health, they received a shipment of Comirnaty on June 29, 2023, and decided to authorize its use for individuals aged six months and older after conducting a thorough and independent review of the evidence.
Infants and children between six months and less than five years of age who have not previously received a full primary series of COVID-19 vaccination should receive three doses of Comirnaty. However, if they have completed a full primary series, authorities say they should receive one booster dose.
The Moderna vaccine, which is also effective against the Omicron XBB.1.5 subvariant, was approved by Health Canada earlier this month. Additionally, the Ministry of Health is currently reviewing a shipment from Novavax for another COVID-19 vaccine that targets the Omicron XBB.1.5 subvariant and is intended for individuals aged 12 and older.
It is anticipated that the National Advisory Committee on Immunization (NACI) will provide guidance on the use of these new COVID-19 vaccines in the coming months.
Health Canada stated in a press release that Canada will have sufficient access to new mRNA vaccine formulations by the fall of 2023. Vaccination remains one of the most effective ways to protect against severe illness, hospitalization, and death from COVID-19, as the evidence indicates that approved vaccines for use in Canada are highly effective.

 News Sources